(Reuters) – Eli Lilly and Co said on Monday (1/11/2021) a trial of its experimental Alzheimer’s drug donanemab showed it slowed by about a third the rate of decline in a combined measure of cognition and function in early-stage victims of the disease. The drug is an antibody designed to remove clumps of the Alzheimer’s-related…
Lilly says Alzheimer’s drug slows clinical decline in mid-stage trial
Jan 11, 2021